Skip to content

Effects of Octacosanol During Taekwondo Training

Octacosanol Supplementation Improves Lipid Profiles and Oxidative Stress During Rapid Weight Loss and High-Intensity Exercise in Taekwondo Athletes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03557476
Enrollment
26
Registered
2018-06-15
Start date
2017-08-01
Completion date
2018-03-01
Last updated
2020-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias, Oxidative Stress

Keywords

Octacosanol, Taekwondo, Lipid Profiles, Oxidative Stress

Brief summary

Taekwondo players undergo rapid reductions of body weight prior to their competition in order to gain a size advantage over the opponent. However, these large weight changes with concomitant high intensity exercise training induce poor lipid profiles and high levels of oxidative stress, which can be detrimental to health and sports performance. Therefore, the purpose of this study was to investigate the ability of the nutritional supplement octacosanol to combat the physiological detriments that can occur from these rapid weight changes paired with high intensity exercise training.

Detailed description

Athletes that participate in weight division sports such as taekwondo, boxing, judo, and wrestling regularly reduce their body weight severely prior to competition in order to gain a size advantage over the opponent while simultaneously meeting their weight division requirements. In general, athletes have acute weight loss of 4-7 kg within 3-4 days of competition, while longer periods of more gradual weight loss of 15-22 kg lasting 3-4 weeks. Although this kind of extreme weight loss can induce metabolic dysfunction, it is repeatedly performed by athletes of weight division sports in order to acquire a more advantageous condition for play. Furthermore, athletes participating in matches tend to obtain excessive weights compared to their weight division during the offseason in order to lift heavier weights during training, and then rapidly lose that weight over a short period of time prior to competition, resulting in the deterioration of physiological function and possibly sports performance. Rapid weight loss with high intensity exercise training also increases oxygen free radical production to a point that exceeds the defense mechanism of antioxidant enzymes in the body and ultimately results in damage to the cells, specifically, the lipid peroxidation of cell membranes. Not only does this decrease physiological function, but sports performance can also decrease as oxidative stress increases due to an interference in metabolic activity, a reduction in vascular function and an increase in systemic inflammation. Octacosanol, a straight-chain, high-molecular-weight, primary aliphatic alcohol minimally contained in the germinal disks of rice bran, wheat and sugar cane, may be able to prevent these deteriorations as it has been shown to provide various health benefits. In fact, previous studies reported that pre-exercise octacosanol intake contributed to enhanced muscular strength, muscular endurance and oxygen transport ability. Additionally, octacosanol supplementation has been shown to improve cardiovascular endurance and heart function in patients with peripheral artery disease, improve levels of low-density and high-density lipoprotein-cholesterol in patients with hypercholesterolemia, and increase glycogen accumulation in mice9. However, the potential beneficial effects of octacosanol intake for reducing free radical production and preventing detrimental physiological function from excessive weight loss with high intensity exercise has not been examined. Thus, the purpose of this study was to investigate the effects of octacosanol supplementation during acute weight loss with high-intensity exercise training on lipid profiles and markers of oxidative stress in taekwondo players.

Interventions

DIETARY_SUPPLEMENTOctacosanol

One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day

DIETARY_SUPPLEMENTPlacebo

A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement

Sponsors

University of Nebraska
CollaboratorOTHER
Kosin University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
17 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

* at least 3 years of experience in national taekwondo competitions * abstain from caffeinated drinks, alcohol, and antioxidant supplements during the whole period of the study

Exclusion criteria

* no history of chronic use of antioxidants, chronic aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) * No cardiovascular, neurological, metabolic or renal diseases * no musculoskeletal injuries

Design outcomes

Primary

MeasureTime frameDescription
Triglycerides6 daysPlasma triglyceride levels
Total Cholesterol6 daysPlasma total cholesterol levels
High-density Lipoprotein6 daysPlasma levels of high-density lipoprotein
Low-density Lipoprotein6 daysPlasma levels of low-density lipoprotein

Secondary

MeasureTime frameDescription
Superoxide Dismutase6 daysPlasma levels of superoxide dismutase
Glutathione Peroxidase6 daysPlasma levels of glutathione peroxidase
Malondialdehyde6 daysPlasma levels of malondialdehyde

Countries

United States

Participant flow

Participants by arm

ArmCount
Octacosanol
Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals. Octacosanol: One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
13
Placebo
A placebo pill was taken twice daily in replacement of the octacosanol supplement Placebo: A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
13
Total26

Baseline characteristics

CharacteristicPlaceboTotalOctacosanol
Age, Continuous18 years
STANDARD_DEVIATION 1
18 years
STANDARD_DEVIATION 1.3
18 years
STANDARD_DEVIATION 1
Body fat8 percentage of body fat
STANDARD_DEVIATION 2
8 percentage of body fat
STANDARD_DEVIATION 2.4
8 percentage of body fat
STANDARD_DEVIATION 2
Height173.9 cm
STANDARD_DEVIATION 6.3
174.3 cm
STANDARD_DEVIATION 3.9
174.7 cm
STANDARD_DEVIATION 1.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
13 Participants26 Participants13 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
South Korea
13 Participants26 Participants13 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
13 Participants26 Participants13 Participants
Weight66.7 kg
STANDARD_DEVIATION 5.7
66.8 kg
STANDARD_DEVIATION 6.2
66.9 kg
STANDARD_DEVIATION 6.7

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 13
other
Total, other adverse events
0 / 130 / 13
serious
Total, serious adverse events
0 / 130 / 13

Outcome results

Primary

High-density Lipoprotein

Plasma levels of high-density lipoprotein

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolHigh-density Lipoprotein71 mg/dLStandard Deviation 4.4
PlaceboHigh-density Lipoprotein49.2 mg/dLStandard Deviation 2.6
Primary

Low-density Lipoprotein

Plasma levels of low-density lipoprotein

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolLow-density Lipoprotein92.6 mg/dLStandard Deviation 8.1
PlaceboLow-density Lipoprotein114.9 mg/dLStandard Deviation 10.8
Primary

Total Cholesterol

Plasma total cholesterol levels

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolTotal Cholesterol164 mg/dLStandard Deviation 12.8
PlaceboTotal Cholesterol173.5 mg/dLStandard Deviation 16.1
Primary

Triglycerides

Plasma triglyceride levels

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolTriglycerides34.9 mg/dLStandard Deviation 7.8
PlaceboTriglycerides110 mg/dLStandard Deviation 8.1
Secondary

Glutathione Peroxidase

Plasma levels of glutathione peroxidase

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolGlutathione Peroxidase66.9 U/gHbStandard Deviation 10.8
PlaceboGlutathione Peroxidase47.1 U/gHbStandard Deviation 9.7
Secondary

Malondialdehyde

Plasma levels of malondialdehyde

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolMalondialdehyde0.25 mmol/mLStandard Deviation 0.1
PlaceboMalondialdehyde0.93 mmol/mLStandard Deviation 0.12
Secondary

Superoxide Dismutase

Plasma levels of superoxide dismutase

Time frame: 6 days

ArmMeasureValue (MEAN)Dispersion
OctacosanolSuperoxide Dismutase1450 U/gHbStandard Deviation 138.9
PlaceboSuperoxide Dismutase1010 U/gHbStandard Deviation 150.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026